Capital Floods into China's Brain-Computer Interface Sector in 2026, with Over RMB 5 Billion Raised and Multiple IPO Filings

　　【Pharmaceutical Network - Industry Trends] In recent years, the brain-computer interface (BCI) and embodied intelligence sectors have benefited from dual advantages in policy support and capital investment, leading to increasingly vigorous industry development. Data shows that in 2025, there were 26 financing rounds completed in China's BCI sector, with a total amount of 1.778 billion yuan. Since 2026, the enthusiasm for financing in the industry has remained strong, with many companies such as Sunnyou and XS Vision having announced their financing plans.
 

On June 19, Sunnyou issued an announcement stating its plan to issue shares to no more than 35 specific investors. The issuance size will not exceed 30% of the total share capital, with the total amount raised capped at RMB 1.366 billion. The funds will be entirely invested in the innovative research and development of high-end rehabilitation medical devices, supplemented by working capital for core business operations. The overall construction period for the project is five years.
 

It is reported that Sunnyou began laying out its brain-computer interface (BCI) R&D in 2015. As of June 2026, two EEG acquisition devices have obtained medical device registration certificates, with four additional non-invasive EEG evoked potential device registration certificates added in May this year. The company has achieved independent full-chain R&D for complete systems, specialized chips, core algorithms, and electrode accessories. Its related products are now deployed in over 800 Grade A tertiary hospitals across China. With a clear pace of commercialization, the channel expansion target for 2026 is to surpass 1,000 medical institutions.
 

On June 17, XS Vision, a developer of invasive brain-computer interfaces, announced the completion of its seed funding round, raising nearly RMB 100 million. The round was led by Matrix Partners China, with participation from Yanyuan Fund, Shuimu Ventures, and Xinglian Capital (Z Fund).
 

XS Vision, incubated by a multidisciplinary brain-computer interface research team from Peking University and ShanghaiTech University, focuses on the development of high-precision neural signal acquisition and closed-loop modulation technologies, aiming to drive breakthroughs in the clinical treatment of severe neurological disorders. The funds raised in this round will be used to develop an invasive visual cortical prosthesis (VCP), fully advancing the independent R&D of wafer-scale, ten-thousand-channel neural stimulation chips, the development of visual reconstruction algorithms and integrated fully implantable brain-computer systems, preclinical validation, and the expansion of the core engineering team.
 

On June 9, Neuracle’s IPO preparatory status was updated to “preparatory work completed.” On June 11, the company submitted its IPO application materials, and the listing application was formally accepted. According to the prospectus, the proposed fundraising amount for this IPO is RMB 2.5 billion. Of this, RMB 1.54 billion will be allocated to brain-computer interface (BCI) research and development projects, RMB 410 million to BCI industrialization projects, and RMB 550 million to supplement working capital.
 

According to available data, Neuracle focuses on “brain-computer interface” (BCI) technology and is professionally engaged in the research and development, production, and sales of BCI-related products. The company has established certain technical barriers in core technological areas such as weak neural signal acquisition, signal analysis, and closed-loop feedback. In the field of invasive BCI, Neuracle’s NEO-ONE SCI (Implantable Brain-Computer Interface System for Hand Motor Function Compensation) received marketing approval from the National Medical Products Administration (NMPA) in March this year. It is indicated for patients aged 18 to 60 years who suffer from quadriplegia due to cervical spinal cord injury and are unable to perform finger grasping movements.
 

In June, Westlake Lingxi completed tens of millions of yuan in Angel+ round financing. Westlake Lingxi Technology (Neuralicorn), incubated by Westlake University, focuses on the research and development of brain-computer interface chips, systems, and intelligent decoding technologies. In the chip sector, the company has established comprehensive R&D capabilities spanning chip design, system integration, and algorithm development, and has strategically positioned itself around high-throughput brain-computer interface chips, implantable brain-computer systems, and neuromodulation technologies.
 

The funds from this round of financing will be primarily allocated to the R&D iteration and industrialization of brain-computer interface (BCI) chips and Chinese language decoding technologies, accelerating the translation of key technological achievements from the laboratory to clinical application scenarios.
 

　　……
 

According to incomplete statistics, since 2026, there have been at least 30 financing events in the domestic brain-computer interface (BCI) sector, with total funding exceeding RMB 5 billion. Industry experts believe that this current wave of investment fervor is a concentrated reflection of the BCI industry’s pivotal transition from “proof of concept” to “industrial implementation.” In the future, those who can first complete product validation, establish viable business models, and build a full-chain ecosystem are expected to gain a competitive edge in the race within this emerging industry.
 

　　Disclaimer: Under no circumstances shall the information contained herein or the opinions expressed constitute investment advice to any person.